Colorectal cancer screening

Revision as of 19:36, 11 November 2014 by Rim Halaby (talk | contribs)
Jump to navigation Jump to search

Colorectal cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Colorectal cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Metastasis Treatment

Primary Prevention

Secondary Prevention

Follow-up

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Colorectal cancer screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Colorectal cancer screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Colorectal cancer screening

CDC on Colorectal cancer screening

Colorectal cancer screening in the news

Blogs on Colorectal cancer screening

Directions to Hospitals Treating Colorectal cancer

Risk calculators and risk factors for Colorectal cancer screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Elliot B. Tapper, M.D., Beth Israel Deaconess Medical Center; Michael Maddaleni, B.S.

Overview

Current guidelines suggest that a colonoscopy is the best screening tool for colon cancer; in fact, colonoscopy detects colon cancer in 98-99% of the cases.[1] A colonoscopy every 10 years reduces the risk of left sided colon cancer but not as much for right sided colon cancer. Right sided colon cancers are more likely to be missed because they are harder to reach and they could be flat, which means they would be harder to detect. Flat growths (non-polypoid) are difficult to detect and are likely to progress to colon cancer than cylindrical polyps [1] Spray on dyes may better help to detect flat growths.

Screening

Colorectal cancer can take many years to develop and early detection of colorectal cancer greatly improves the chances of a cure. The U.S. Preventive Services Task Force (USPSTF) recommends screening all patients aged 50-75 for colorectal cancer.[2]

The American College of Gastroenterology recommends:[3]

  • Screening in African Americans should begin at age 45 years.
  • CT colonography every 5 years is the radiographic screening alternative, when patients decline colonoscopy.
  • Fecal immunochemical test for blood (FIT) is preferred over guaiac-based fecal occult blood testing.

The recommended modalities are discussed below.

Fecal Occult Blood Testing

Fecal occult blood test (FOBT): a test for blood in the stool. Two types of tests can be used for detecting occult blood in stools i.e. guaiac based (chemical test) and immunochemical. The sensitivity of immunochemical testing is superior to that of chemical testing without an unacceptable reduction in specifity. [4]

Endoscopy

Sigmoidoscopy: A lighted probe (sigmoidoscope) is inserted into the rectum and lower colon to check for polyps and other abnormalities.

Colonoscopy: A lighted probe called a colonoscope is inserted into the rectum and the entire colon to look for polyps and other abnormalities that may be caused by cancer. A colonoscopy has the advantage that if polyps are found during the procedure they can be immediately removed. Tissue can also be taken for biopsy. The American Society for Gastrointestinal Endoscopy has released quality indicators for screening colonoscopy, which include:[5]

  • Documentation of prep quality
  • Photo documentation of cecal intubation
  • Withdrawal time of 6 minutes or more
  • Adenoma detection rate of greater than 25% in males and 15% in females greater than 50 years old.

Other Screening Techniques

  • Double contrast barium enema (DCBE): First, an overnight preparation is taken to cleanse the colon. An enema containing barium sulfate is administered, then air is insufflated into the colon, distending it. The result is a thin layer of barium over the inner lining of the colon which is visible on X-ray films. A cancer or a precancerous polyp can be detected this way. This technique can miss the (less common) flat polyp.
  • Virtual colonoscopy replaces X-ray films in the double contrast barium enema (above) with a special computed tomography scan and requires special workstation software in order for the radiologist to interpret. This technique is approaching colonoscopy in sensitivity for polyps. However, any polyps found must still be removed by standard colonoscopy.
  • Blood tests: Measurement of the patient's blood for elevated levels of certain proteins can give an indication of tumor load. In particular, high levels of carcinoembryonic antigen (CEA) in the blood can indicate metastasis of adenocarcinoma. These tests are frequently false positive or false negative, and are not recommended for screening, it can be useful to assess disease recurrence.
  • Stool DNA testing detects DNA shed into the stool from the cells of pre-malignant adenomas and cancers. The DNA is not degraded during the digestive process and remain stable in the stool. Capture, followed by Polymerase Chain Reaction amplifies the DNA to detectable levels for assay. Clinical studies have shown a cancer detection sensitivity of 71%-91%[6], and may be more sensitive than fecal immunochemical testing.[7]

Genetic Counseling

References

  1. 1.0 1.1 American Society of Clinical Oncology. 2010. Progress in Cancer Screening. http://owl.english.purdue.edu/owl/resource/560/10/
  2. Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.Ann Intern Med. 2008;149:627-637.
  3. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009.Am J Gastroenterol. 2009 Mar;104(3):739-50.
  4. Weitzel JN: Genetic cancer risk assessment. Putting it all together. Cancer 86:2483,1999. PMID 10630174
  5. Rex DK, Petrini JL, Baron TH, Chak A, Cohen J, Deal SE; et al. (2006). "Quality indicators for colonoscopy". Am J Gastroenterol. 101 (4): 873–85. doi:10.1111/j.1572-0241.2006.00673.x. PMID 16635231.
  6. B. Greenwald (2006). "The DNA Stool Test - An Emerging Technology in Colorectal Cancer Screening".
  7. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP; et al. (2014). "Multitarget stool DNA testing for colorectal-cancer screening". N Engl J Med. 370 (14): 1287–97. doi:10.1056/NEJMoa1311194. PMID 24645800.


Template:WikiDoc Sources